ABSTRACT

HIV REPLICATION INHIBITING PYRIMIDINES

This invention concerns the use of compounds of formula



(I)

the *N*-oxides, the pharmaceutically acceptable addition salts, quaternary amines and the stereochemically isomeric forms thereof, wherein -a^1=a^2-a^3=a^4- forms a phenyl, pyridinyl, pyrimidinyl, pyridazinyl or pyrazinyl with the attached vinyl group; n is 0 to 4; and where possible 5; R^1 is hydrogen, aryl, formyl, C_{1-6}alkylcarbonyl, C_{1-6}alkyl, C_{1-6}alkyloxycarbonyl, substituted C_{1-6}alkyl, or substituted C_{1-6}alkyloxyC_{1-6}alkylcarbonyl; each R^2 independently is hydroxy, halo, optionally substituted C_{1-6}alkyl, C_{2-6}alkenyl or C_{2-6}alkynyl, C_{3-7}cycloalkyl, C_{1-6}alkyloxy, C_{1-6}alkyloxycarbonyl, carboxyl, cyano, nitro, amino, mono- or di(C_{1-6}alkyl)amino, polyhalomethyl, polyhalomethyloxy, polyhalomethylthio, -S(=O)$_p$$R^6$, -NH-S(=O)$_p$$R^6$, -C(=O)$R^6$, -NHC(=O)H, -C(=O)$NHNH_2$, -NHC(=O)$R^6$,-C(=NH)$R^6$ or a 5-membered heterocyclic ring; p is 1 or 2; L is optionally substituted C_{1-10}alkyl, C_{2-10}alkenyl, C_{2-10}alkynyl or C_{3-7}cycloalkyl; or L is -X-R^3 wherein R^3 is optionally substituted phenyl, pyridinyl, pyrimidinyl, pyrazinyl or pyridazinyl; X is -NR^1-, -NH-NH-, -N=N-, -O-, -C(=O)-, -CHOH-, -S-, -S(=O)- or -$S(=O)_2$-; Q is hydrogen, C_{1-6}alkyl, halo, polyhalo-C_{1-6}alkyl or an optionally substituted amino group; Y represents hydroxy, halo, C_{3-7}cycloalkyl, optionally substituted C_{1-6}alkyl, C_{2-6}alkenyl or C_{2-6}alkynyl, C_{1-6}alkyloxy, C_{1-6}alkyloxycarbonyl, carboxyl, cyano, nitro, amino, mono- or di(C_{1-6}alkyl)amino, polyhalomethyl, polyhalomethyloxy, polyhalomethylthio, -S(=O)$_p$$R^6$, -NH-S(=O)$_p$$R^6$, -C(=O)$R^6$, -NHC(=O)H, -C(=O)$NHNH_2$, -NHC(=O)$R^6$,-C(=NH)$R^6$ or aryl; aryl is optionally substituted phenyl; Het is an optionally substituted heterocyclic radical; for the manufacture of a medicine for the treatment of subjects suffering from HIV (Human Immunodeficiency Virus) infection.

T0010